香蕉视频

Umang Swami
( out of 75 reviews )

Umang Swami, MD

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
Salt Lake City
801-587-4644

Sugar House Health Center

Salt Lake City
801-581-2000

  • Umang Swami is an Assistant Professor in the Division of Oncology, Department of Internal Medicine at Huntsman Cancer Institute, 香蕉视频 of Utah. He is a specialist in medical oncology with a focus on genitourinary cancers. He completed his Medical School from Sawai Man Singh Medical College, India. Thereafter, he worked as a Visiting Scientist at Montefiore-Einstein Cancer Center, NY, and collaborated on phase I studies of novel drugs and regimens for patients with refractory or advanced solid tumors. He did his residency training in Internal Medicine at St. Barnabas Hospital, NY, Hematology-Oncology fellowship from the 香蕉视频 of Iowa, and an MS in Clinical Investigations from the College of Public Health at the 香蕉视频 of Iowa.


    He has published over 110 peer-reviewed articles and book chapters and presented his research at various international conferences, including ASCO, AACR, and ASBMT. He is a reviewer and editor of multiple journals and a member of various professional societies like ASCO, AACR, ESMO, and SITC. He serves on the ASCO guideline panels for systemic melanoma therapy, immune-related adverse events management, and the Multi-Site Guideline Advisory Group. In addition, he is a current member of the Institutional Review Board (IRB), Radioactive Drug Research Committee (RDRC), and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC) at the 香蕉视频 of Utah. He has mentored medical students, residents, and fellows interested in oncology research.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 75 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Swami is very thorough in his explanations and takes time with his patients for any questions that might come up.

    October 18, 2024
    HUNTSMAN CANCER CENTER

    Very good with patients and let's you ask questions and will answer to your level and a very nice doctor

    September 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Swami is the BEST!!!

    September 06, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Swami has a strong accent, that for me, made it challenging to understand what he was saying. However, he was patient with me and did not mind me asking him to repeat or clarify information. He is extremely knowledgeable and very determined to find the absolute best care. I have complete confidence in him and feel fortunate to have him guiding my treatment.

    September 06, 2024
    HUNTSMAN CANCER CENTER

    Excellent explanation of the Clinical Trials and I am hopeful that I will get help with the Prostate Cancer.

    July 17, 2024
    HUNTSMAN CANCER CENTER

    Dr Umang Swami has been helping me for 2.5 years. He has taking excelnt care of me. Thank you.

    July 11, 2024
    HUNTSMAN CANCER CENTER

    there. Is a very good doctor and had my interest in mind when putting together my plan for action

    July 11, 2024
    HUNTSMAN CANCER CENTER

    Only able to see his assistant

    July 11, 2024
    HUNTSMAN CANCER CENTER

    Very considerate, professional, and deliberate with the out lined care plan.

    See More Patient Comments

  • Umang Swami is an Assistant Professor in the Division of Oncology, Department of Internal Medicine at Huntsman Cancer Institute, 香蕉视频 of Utah. He is a specialist in medical oncology with a focus on genitourinary cancers. He completed his Medical School from Sawai Man Singh Medical College, India. Thereafter, he worked as a Visiting Scientist at Montefiore-Einstein Cancer Center, NY, and collaborated on phase I studies of novel drugs and regimens for patients with refractory or advanced solid tumors. He did his residency training in Internal Medicine at St. Barnabas Hospital, NY, Hematology-Oncology fellowship from the 香蕉视频 of Iowa, and an MS in Clinical Investigations from the College of Public Health at the 香蕉视频 of Iowa.


    He has published over 110 peer-reviewed articles and book chapters and presented his research at various international conferences, including ASCO, AACR, and ASBMT. He is a reviewer and editor of multiple journals and a member of various professional societies like ASCO, AACR, ESMO, and SITC. He serves on the ASCO guideline panels for systemic melanoma therapy, immune-related adverse events management, and the Multi-Site Guideline Advisory Group. In addition, he is a current member of the Institutional Review Board (IRB), Radioactive Drug Research Committee (RDRC), and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC) at the 香蕉视频 of Utah. He has mentored medical students, residents, and fellows interested in oncology research.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Externship Cancer Therapy Evaluation Program Elective - National Cancer Institute Externship
    Hematology Oncology - 香蕉视频 of Iowa Hospitals and Clinics Fellow
    Graduate Training Clinical Investigation - 香蕉视频 of Iowa College of Public Health M.S.C.I
    Internal Medicine - St. Barnabas Hospital Resident
    Professional Medical Medicine/Surgery - Sawai Man Singh Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U (2024). Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. Kidney Cancer, 8(1), 135-142. ()
    2. Swami U, Xie B, Young C, Ramaswamy K, El-Chaar N, Gao W, Yang H, Wang Y, Mucha L (2024). Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer. Prostate. ()
    3. Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgi J, Mileti M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castaeda DM, Rey-Crdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR (2024). Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer, 22(6), 102198. ()
    4. Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Flchon A, Jain RK, Swami U, Bupathi M, Barthlmy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jrgensmeier JM, Tagawa ST (2024). Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer. Clin Cancer Res, 30(15), 3179-3188. ()
    5. Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, Chaar NE, Gupta S (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future Oncol, 1-14. ()
    6. Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, Agarwal N, Spratt DE (2024). Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. J Urol, 101097JU0000000000004158. ()
    7. Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N (2024). Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open, 7(7), e2419966. ()
    8. Goel S, Negassa A, Ghalib MH, Chaudhary I, Desai K, Shah U, Swami U, Cohen B, Maitra R, Mani S (2024). Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials: A Meta-Analysis. JAMA Netw Open, 7(7), e2421485. ()
    9. Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami U (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA Netw Open, 7(7), e2423186. ()
    10. Roy S, Saad F, Sun Y, Malone S, Spratt DE, Kishan AU, Wallis CJD, Jia AY, Mohamad O, Swami U, Ong M, Agarwal N, Chowdhury S, Morgan SC (2024). Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial. Eur J Cancer, 211, 114197. ()
    11. Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta S (2024). Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. Cancers (Basel), 16(11). ()
    12. Tung N, Ricker C, Messersmith H, Balmaa J, Domchek S, Stoffel EM, Almhanna K, Arun B, Chavarri-Guerra Y, Cohen SA, Cragun D, Crew KD, Hall MJ, Idos G, Lopez G, Pal T, Pirzadeh-Miller S, Pritchard C, Rana HQ, Swami U, Vidal GA (2024). Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol, JCO2400662. ()
    13. Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. Eur Urol Oncol. ()
    14. Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA Netw Open, 7(5), e249417. ()
    15. Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI. JCO Precis Oncol, 8, e2300574. ()
    16. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC Cancer, 24(1), 493. ()
    17. Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK (2024). Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations. Eur Urol Focus. ()
    18. Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U (2024). Cabozantinib with immune checkpoint inhibitor聽versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer, 130(15), 2621-2628. ()
    19. Roy S, Saad F, Malone S, Agarwal N, Mohamad O, Morgan SC, Malone J, Swami U, Jia AY, Gebrael G, Mendiratta P, Brown JR, Rao SK, Sun Y, Wallis CJD, Chi KN, Chowdhury S, Kishan AU, Spratt DE (2023). Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study. Eur Urol, 85(4), 398-400. ()
    20. Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N (2024). Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. Prostate, 84(9), 888-892. ()
    21. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist, 29(5), 450-e725. ()
    22. Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami U (2023). Predictors of response to neoadjuvant therapy in urothelial cancer. Crit Rev Oncol Hematol, 194, 104236. ()
    23. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Agarwal N, Swami U, Sirohi D (2024). Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Hum Pathol, 144, 28-33. ()
    24. Al-Akhras A, Hage Chehade C, Narang A, Swami U (2024). PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape. Life (Basel), 14(2). ()
    25. Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan S (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) na茂ve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. J Immunother Cancer, 12(1). ()
    26. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. Urol Pract, 11(1), 32-35. ()
    27. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Reply by Authors. Urol Pract, 101097UPJ000000000000047102. ()
    28. Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, Agarwal N, Swami U (2023). Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. Cancers (Basel), 15(21). ()
    29. Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J (2023). Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol, 41(30), 4794-4820. ()
    30. Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N (2023). Advances in the treatment of metastatic prostate cancer. Trends Cancer, 9(10), 840-854. ()
    31. Gebrael G, Zengin Z, Swami U (2023). Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. JCO Precis Oncol, 7, e2300397. ()
    32. Tripathi N, Thomas VM, Sayegh N, Gebrael G, Chigarira B, Jo Y, Li H, Sahu KK, Nussenzveig R, Nordblad B, Swami U, Agarwal N, Maughan BL (2023). Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer. Prostate, 83(16), 1602-1609. ()
    33. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol, 14, 1229823. ()
    34. Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, Agarwal N (2023). Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. JAMA Netw Open, 6(8), e2326546. ()
    35. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer, 11(8). ()
    36. Gebrael G, Sahu KK, Chigarira B, Tripathi N, Mathew Thomas V, Sayegh N, Maughan BL, Agarwal N, Swami U, Li H (2023). Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. Cancers (Basel), 15(14). ()
    37. Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Strivastava A, McFarland T, Maughan BL, Swami U, Agarwal N (2023). Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. Prostate Cancer Prostatic Dis. ()
    38. Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2023). Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis. ()
    39. Marshall MB, Dindinger-Hill K, Swami U, Lyden S, Sanchez A (2023). Intraperitoneal seeding of a testicular mixed germ cell tumor following spontaneous intraperitoneal mass rupture with associated anti-NMDA paraneoplastic encephalitis. Urol Case Rep, 48, 102427. ()
    40. Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Lalibert F, Emond B, Agarwal N (2023). Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. Clin Genitourin Cancer. ()
    41. Gebrael G, Thomas VM, Swami U, Agarwal N (2023). The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice. Oncologist, 28(9), 746-749. ()
    42. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. Oncologist, 28(8), 737-e693. ()
    43. Swami U, Hong A, El-Chaar NN, Ramaswamy K, Diessner BJ, Blauer-Peterson CJ, Sandin R, Nimke D, Agarwal N (2023). The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer. J Urol, 101097JU0000000000003370. ()
    44. McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U (2022). Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. Biomedicines, 10(12). ()
    45. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N (2022). External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. Mol Cancer Ther, 21(12), 1857-1861. ()
    46. Sayegh N, Tripathi N, Agarwal N, Swami U (2022). Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. Onco Targets Ther, 15, 1047-1055. ()
    47. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N (2022). Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol, 12, 966534. ()
    48. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583. ()
    49. Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N (2022). SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res, 28(22), 4917-4925. ()
    50. Sahu KK, Tripathi N, Agarwal N, Swami U (2022). Relugolix in the management of prostate cancer. Expert Rev Anticancer Ther, 22(9), 891-902. ()
    51. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 27(10), e815-e818. ()
    52. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7. ()
    53. Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U (2022). Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Eur Urol Focus, 9(1), 106-109. ()
    54. Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC (2021). Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist, 27(3), 220-227. ()
    55. Mathew Thomas V, Tripathi N, Agarwal N, Swami U (2022). Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther, 22(4), 1-7. ()
    56. Sayegh N, Swami U (2022). Editorial Comment. J Urol, 101097JU000000000000242501. ()
    57. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol, 39(36), 4073-4126. ()
    58. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M (2021). Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol, 39(35), 3978-3992. ()
    59. McFarland TR, Tandar CE, Agarwal N, Swami U (2021). Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. Cancer Treat Res Commun, 29, 100480. ()
    60. Swami U, Agarwal N (2021). Drug development in metastatic prostate cancer: lessons from ACIS. Lancet Oncol. ()
    61. Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzveig R, Kohli M, Pal SK, Agarwal N (2021). Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers (Basel), 13(19). ()
    62. Sayegh N, Swami U, Agarwal N (2021). Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract, OP2100206. ()
    63. Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 26(9), 751-760. ()
    64. Swami U, Agarwal N (2021). Editorial Comment. J Urol, 206, 101097JU000000000000212101. ()
    65. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 26, 1006-e2129. ()
    66. McFarland TR, Kessel A, Swami U, Agarwal N (2021). Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. Am J Transl Res, 13(7), 7427-7439. ()
    67. Asare EA, Swami U, Stewart JH 4th (2021). Landmark Series on Disparities in Surgical Oncology: Melanoma. Ann Surg Oncol, 28, 6986-6993. ()
    68. Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM, Stein JE, Grivas P, Zakharia Y, Singh N (2020). Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med, 9(12), 1033. ()
    69. Zawit M, Swami U, Awada H, Arnouk J, Milhem M, Zakharia Y (2021). Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med, 9(12), 1038. ()
    70. Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2020). The dark side of immunotherapy. Ann Transl Med, 9(12), 1041. ()
    71. Venkatachalam S, McFarland TR, Agarwal N, Swami U (2021). Immune Checkpoint Inhibitors in Prostate Cancer. . Cancers (Basel), 13(9), 2187.
    72. Rieth JM, Swami U, Mott SL, Zanaty M, Henry MD, Bossler AD, Greenlee JD, Zakharia Y, Vanneste M, Jennings B, Milhem MM (2021). Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. Cancers (Basel), 13(7). ()
    73. Swami U, Grivas P, Pal SK, Agarwal N (2021). Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treat Res Commun, 27, 100325. ()
    74. Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2020). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer, 9(1). ()
    75. Kessel A, Kohli M, Swami U (2021). Current management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun, 28, 100384. ()
    76. Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U (2020). Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs. ()
    77. Swami U, Chennamadhavuni A, Borcherding N, Bossler AD, Mott SL, Garje R, Zakharia Y, Milhem M (2020). Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Antibiotics (Basel), 9(11). ()
    78. Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma. J Urol, 205(3), 101097JU0000000000001412. ()
    79. Zhu H, Swami U, Preet R, Zhang J (2020). Harnessing DNA Replication Stress for Novel Cancer Therapy. Genes (Basel), 11(9), E990.
    80. Swami U, Agarwal N (2020). Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treat Res Commun, 25, 100205. ()
    81. Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM (2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Curr Med Res Opin, 1-11. ()
    82. Swami U, Nussenzveig RH, Agarwal N (2020). Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clin Cancer Res. ()
    83. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656. ()
    84. Swami U, McFarland TR, Nussenzveig R, Agarwal N (2020). Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer, 6(8), 702-715. ()
    85. Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749. ()
    86. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P (2020). Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol, JCO2000198. ()
    87. Mobley EM, Swami U, Mott S, Ounda A, Milhem M, Monga V (2020). A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers. Oncol Res Treat, 1-6. ()
    88. Johnson E, Nussenzveig R, Agarwal N, Swami U (2019). Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 21(1), 75-81. ()
    89. Swami U, Yap JT, Agarwal N (2019). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA Oncol, 6(2), 225-226. ()
    90. Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019). Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers (Basel), 11(12). ()
    91. Goel S, Swami U, Kumar K, Dittrich C, Reyderman L, Jain M, Aisner J, Song J, Petrylak DP (2019). A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. Cancer Chemother Pharmacol, 84(3), 567-578. ()
    92. Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M (2019). Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. J Oncol, 2019, 1856594. ()
    93. Snyders T, Chakos D, Swami U, Latour E, Chen Y, Fleseriu M, Milhem M, Zakharia Y, Zahr R (2019). Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary. ()
    94. Swami U, Pal SK, Agarwal N (2019). Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. JAMA Oncol. ()
    95. Swami U, Grivas P, Agarwal N (2019). The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. Oncologist, 24(5), 580-583. ()
    96. Swami U, Swick B, Zakharia Y, Milhem M (2019). Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Rep Oncol Med, 2019, 4683531. ()
    97. Swami U, Monga V, Freesmeier M, Zhang W, Bossler AD, Zakharia Y, Milhem M (2019). Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. Melanoma Res. ()
    98. Luther C, Swami U, Zhang J, Milhem M, Zakharia Y (2018). Advanced stage melanoma therapies: Detailing the present and exploring the future. Crit Rev Oncol Hematol, 133, 99-111. ()
    99. Grogan N, Swami U, Bossler AD, Zakharia Y, Milhem M (2018). Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res, 28(6), 600-604. ()
    100. Swami U, Zakharia Y, Zhang J (2018). Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother, 41(8), 359-360. ()
    101. Monga V, Swami U, Tanas M, Bossler A, Mott SL, Smith BJ, Milhem M (2018). A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.LID - E53 [pii]LID - 10.3390/cancers10020053 [doi]. Cancers (Basel), 10(2). ()
    102. Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M (2017). Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget, 8(51), 89182-89193. ()
    103. Swami U, Shah U, Goel S (2017). Eribulin in non-small cell lung cancer: challenges and potential strategies. Expert Opin Investig Drugs, 26(4), 495-508. ()
    104. Swami U, Shah U, Goel S (2015). Eribulin in Cancer Treatment. Mar Drugs, 13(8), 5016-58. ()
    105. Swami U, Annunziata G, Fulger I (2014). Experience with vena cava filters at a large community hospital and level-I trauma center: indications, complications, and compliance barriers. Clin Appl Thromb Hemost, 20(5), 546-52. ()
    106. Hou JY, Aparo S, Ghalib M, Chaudhary I, Shah U, Swami U, Einstein M, Goldberg GL, Mani S, Goel S (2013). Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010. Gynecol Oncol, 131(1), 163-8. ()
    107. Swami U, Chaudhary I, Ghalib MH, Goel S (2011). Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol, 81(2), 163-84. ()
    108. Mani S, Swami U (2010). Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc), 46(9), 641-53. ()

    Review

    1. Al-Akhras A, Hage Chehade C, Narang A, Swami U (2024). PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape. [Review]. Life (Basel), 14(2). ()
    2. Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami U (2023). Predictors of response to neoadjuvant therapy in urothelial cancer. [Review]. Crit Rev Oncol Hematol, 194, 104236. ()
    3. Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N (2023). Advances in the treatment of metastatic prostate cancer. [Review]. Trends Cancer, 9(10), 840-854. ()
    4. Sayegh N, Tripathi N, Agarwal N, Swami U (2022). Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. [Review]. Onco Targets Ther, 15, 1047-1055. ()
    5. Sahu KK, Tripathi N, Agarwal N, Swami U (2022). Relugolix in the management of prostate cancer. [Review]. Expert Rev Anticancer Ther, 22(9), 891-902. ()
    6. Swami U, Shah U, Goel S (2017). Eribulin in non-small cell lung cancer: challenges and potential strategies. [Review]. Expert Opin Investig Drugs, 26(4), 495-508. ()
    7. Swami U, Shah U, Goel S (2015). Eribulin in Cancer Treatment. [Review]. Mar Drugs, 13(8), 5016-58. ()
    8. Swami U, Goel S, Mani S (2013). Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. [Review]. Curr Drug Targets, 14(7), 777-97. ()
    9. Swami U, Chaudhary I, Ghalib MH, Goel S (2012). Eribulin -- a review of preclinical and clinical studies. [Review]. Crit Rev Oncol Hematol, 81(2), 163-84. ()

    Book Chapter

    1. Rathi N, Lin E, Kessel A, Agarwal N (2021). Recent Advances in the Treatment of Metastatic Prostate Cancer. DOI:https://doi.org/10.1016/j.yao.2021.02.022 . In Advances in Oncology REVIEW ARTICLE (1, pp. 263-272).
    2. Swami U, Shah U, Goel S (2015). Marine sponge derived Eribulin in preclinical and clinical studies for cancer. In Handbook of Anticancer Drugs from Marine Origin (pp. 59-100). Cham, Switzerland: Springer International Publishing.

    Commentary

    1. Gebrael G, Sayegh N, Swami U (2023). When Would You Use Doublet Therapy and Not Triplet Therapy for a Patient With Newly Diagnosed mHSPC? ASCO Daily News.
    2. Gebrael G, Sayegh N, Swami U (2023). SPOP Mutations as First Predictive Biomarker for Treatment Selection in De Novo Metastatic Hormone-Sensitive Prostate Cancer. ASCO Daily News.
    3. Sayegh N, Swami U, Agarwal N (2022). Prostate Cancer Breaking News: ASCO 2022. American Urological Association.

    Case Report

    1. Swami U, Swick B, Zakharia Y, Milhem M (2019). Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Rep Oncol Med, 2019, 4683531. ()
    2. Goyal A, Soul D, Annunziata G, Swami U, Choudhury M (Winter 2014). A self destructing reaction to a self destructive habit: Levamisole tainted cocaine causing autoimmune vasculitis. 8(1).

    Editorial

    1. Gebrael G, Zengin Z, Swami U (2023). Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. JCO Precis Oncol, 7, e2300397. ()
    2. Swami U, Sayegh N, Agarwal N (2021). Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer. Eur Urol, 81(3), 263-265. ()
    3. Sayegh N, Agarwal N, Swami U (2021). Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. Eur Urol Oncol, 4(4), 553-557. ()
    4. Sayegh N, Agarwal N, Swami U (2021). Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. Eur Urol Oncol, 4(4), 553-557. ()
    5. Swami U, Milhem M (2021). Cancer immunotherapy: recent advances and challenges. Ann Transl Med, 9(12), 1032. ()
    6. Barata P, Swami U, Agarwal N (2020). The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Rev Anticancer Ther, 20(3), 147-150. ()
    7. Pal SK, Swami U, Agarwal N (2019). Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. Eur Urol, 77(1), 22-23. ()
    8. Rathi N, Maughan BL, Agarwal N, Swami U (2019). The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. Transl Cancer Res, 8(8), E1-E6. ()
    9. Pal SK, Swami U, Agarwal N (2019). Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. Eur Urol, 77(1), 22-23. ()
    10. Swami U, Nussenzveig RH, Haaland B, Agarwal N (2019). Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Ann Transl Med, 7(Suppl 1), S18. ()
    11. Swami U, Monga V, Milhem M (2017). Gastrointestinal stromal tumors-are we stuck and the way forward. Transl Gastroenterol Hepatol, 2, 93. ()

    Letter

    1. Roy S, Saad F, Malone S, Agarwal N, Mohamad O, Morgan SC, Malone J, Swami U, Jia AY, Gebrael G, Mendiratta P, Brown JR, Rao SK, Sun Y, Wallis CJD, Chi KN, Chowdhury S, Kishan AU, Spratt DE (2023). Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study. [Letter to the editor]. Eur Urol, 85(4), 398-400. ()
    2. Swami U, Antonarakis ES, Agarwal N (2021). Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. [Letter to the editor]. Eur Urol, 79(3), e94-e95. ()
    3. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol, 11(4), 724-726. ()
    4. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol, 11(4), 724-726. ()
    5. Swami U, Smith M, Zhang J (2018). Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. [Letter to the editor]. J Thorac Oncol, 13(9), e183-e184. ()
    6. Swami U, Smith M, Zhang J (2018). Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. [Letter to the editor]. J Thorac Oncol, 13(9), e183-e184. ()
    7. Swami U, Ma D, Zhang J (2018). Response to Erlotinib in a聽Patient with Compound EGFR L747S and Exon 19聽Deletion. [Letter to the editor]. J Thorac Oncol, 13(7), e129-e130. ()
    8. Swami U, Ma D, Zhang J (2018). Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. [Letter to the editor]. J Thorac Oncol, 13(7), e129-e130. ()
    9. Swami U, Lenert P, Furqan M, Abu Hejleh T, Clamon G, Zhang J (2018). Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? [Letter to the editor]. J Thorac Oncol, 13(6), e102-e103. ()
    10. Swami U, Lenert P, Furqan M, Abu Hejleh T, Clamon G, Zhang J (2018). Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? [Letter to the editor]. J Thorac Oncol, 13(6), e102-e103. ()

    Abstract

    1. JD Tward, SB Johnson, KE Kokeny, S Lloyd, DM Cannon, CB Dechet, Oneil B, Stephenson RA, Boucher KM, Kohli M, Gupta S, Swami U, Maughan BL, Agarwal N (2024). Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone. [Abstract]. 42(4_suppl).
    2. Srivastava A, Fortuna GG, Chigarira B, Dal E, Chehade CH, Gebrael G, Narang A, Agarwal N, Swami U, Li Haoran (2024). The utility of ChatGPT in subspecialty consultation for patients (pts) with metastatic genitourinary (GU) cancer. [Abstract]. 42(4_suppl).
    3. Jo Y, Tripathi N, Roy S, Thomas VM, Fortuna GG, Chehade CH, Gebrael G, Narang A, Campbell P, Gupta S, Maughan BL, Agarwal N, Swami U (2024). Disparities in the incidence of next-generation sequencing (NGS) among patients (pts) with advanced or metastatic prostate cancer (mPC) and urothelial carcinoma (mUC). [Abstract]. 42(4_suppl).
    4. Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Fortuna GG, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix. [Abstract]. 42(4_suppl).
    5. Swami U, Maughan BL, Boucher KM, Nordblad B, Lloyd J, Batten J, Phunrab TK, Quertinmont J, Kohli M, Gupta S, Agarwal N (2024). Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial. [Abstract]. 42(4_suppl).
    6. Gebrael G, Jo Y, Swami U, Plets M, Chehade CH, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, HA Hussain M, Dorff TB, Lara PN, Lerner SP, Thompson IM, Agarwal N (2024). Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial. [Abstract]. 42(4_suppl).
    7. Tripathi N, Gebrael G, Sahu KK, Balasubramanian I, Caparas C, Thomas VM, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta S (2024). Treatment patterns and outcomes by age in metastatic urothelial carcinoma (mUC): A retrospective tertiary cancer center analysis. [Abstract]. 42(4_suppl).
    8. Thomas VM, Moynier C, Boucher KM, Nordblad B, Clement S, Esplin M, Kohli M, Gupta S, Maughan BL, Agarwal N, Swami U (2024). Borxpten: A phase II study of bortezomib (B) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion. [Abstract]. 42(4_suppl).
    9. Fortuna GG, Grass DG, Maughan BL, Jain RK, Dechet CB, Beck J, Schuetz E, Sanchez A, Oneil B, Poch MA, Li R, Lloyd S, Tward JD, Phunrab TK, Hawks J, Swami U, Boucher KM, Agarwal N, Gupta S (2024). NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma. [Abstract]. 42(4_suppl).
    10. Fortuna GG, Moynier C, Boucher KM, Nordblad B, Covington M, Fine G, Clement S, Esplin M, Kohli M, Gupta S, Maughan BL, Agarwal N, Swami U (2024). CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). [Abstract]. 42(4_suppl).
    11. Fortuna GG, Nazari S, Swami U, Elliott A, Gebrael G, Bagrodia A, Puri D, Nabhan C, McKay RR, Antonarakis ES, Agarwal N (2024). Survival outcomes in patients (pts) with prostatic cancer (PCa) based on pathologically confirmed sites of metastasis. [Abstract]. 42(4_suppl).
    12. Jain RK, Swami U, Bilen MA, Boucher KM, Brown JT, Chahoud J, Gupta S, Agarwal N, Sonpavde GP, Maughan BL (2024). Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). [Abstract]. 42(4_suppl).
    13. Chehade CH, Gebrael G, Srivastava A, Tripathi N, Sayegh N, Thomas VM, Fortuna GG, Chigarira B, Nordblad B, Campbell P, Tandar C, Li H, Maughan BL, Agarwal N, Swami U (2024). Disease characteristics, survival outcomes, and tumor molecular landscape in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) harboring CDK12 alterations (CDK12a) receiving intensified androgen deprivation therapy (ADTi). [Abstract]. 42(4_suppl).
    14. Dal E, Srivastava A, Chigarira B, Chehade CH, Narang A, Gebrael G, Ji R, Agarwal N, Swami U, Li H (2024). Comparative effectiveness of ChatGPT 4.0 and medical oncologists in telemedicine-based management of metastatic prostate carcinoma (mPC). [Abstract]. 42(4_suppl).
    15. Roy S, Malone S, Sun Y, JD Wallis C, Kishan AU, Morgan SC, Gebrael G, Swami U, Jia A, Brown JR, Saad F, Agarwal N, Spratt DE (2024). Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial. [Abstract]. 42(4_suppl).
    16. Thomas VM, Jo Y, Tripathi N, Roy S, Chigarira B, Dal E, Gebrael G, Chehade CH, Sayegh N, Fortuna GG, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U (2024). Treatment (Rx) trends and attrition with lines of therapy in patients (pts) with advanced urothelial carcinoma (aUC). [Abstract]. 42(4_suppl).
    17. Swami U, Nazari S, Gebrael G, Elliott A, Bagrodia A, Puri D, Nabhan C, McKay RR, Antonarakis ES, Agarwal N (2024). Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets). [Abstract]. 42(4_suppl).
    18. Swami U, Brown J, Turner A, Haaland B, Jones K, Thomas VM, Sahu KK, Li H, Phunrab TK, Batten J, Maxwell L, Lloyd J, Kohli M, Gupta S, Thorne K, Maughan BL, Agarwal N (2023). AtezoCab: A phase II study of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with non-measurable disease (NMD). (suppl 6; abstract TPS295). [Abstract]. 41, 聽suppl 6; abstract TPS295.
    19. Swami U, Faust C, Leonhart S, Haaland B, Jones K, Li H, Sahu KK, Thomas VM, Phunrab TK, Batten J, Maxwell L, Lloyd J, Kohli M, Gupta S, Thorne K, Maughan BL, Agarwal N (2023). ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). [Abstract]. 41, suppl 6; abstract TPS294.
    20. Swami U, Xie B, Ramaswamy K, El-Chaar NN, Gao W, Yang H, Wang Y, Young C, Mucha L (2023). Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). [Abstract]. 41, suppl 6; abstract 109.
    21. Sahu KK, Li H, Thomas VM, Benson M, Hawaks J, Brown J, Thorne K, Sherwin K, Cheney J, Boucher KM, Gupta S, Kohli M, Swami U, Agarwal A, Maughan BL (2023). A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR). [Abstract]. 41, suppl 6; abstract 364.
    22. Li H, Sahu KK, Kumar SA, Thomas VM, Tripathi N, Gebrael G, Sayegh N, Chigarira B, Jo Y, Swami U, Gupta S, Maughan BL, Agarwal N (2023). Access to care and health care quality metrics in urban versus rural patients (pts) with advanced prostate cancer (aPC). [Abstract]. 41, suppl 6; abstract 37.
    23. Thomas VM, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Jo Y, Nussenzveig R, Sahu KK, Li H, Tandar C, Goel D, McFarland TR, Brundage J, Maughan BL, Swami U, Agarwal N (2023). Association of obesity with tumor differential gene expression and gene set enrichment pathways in advanced prostate adenocarcinoma (PCa). [Abstract]. 41, suppl 6; abstract 231.
    24. Sahu KK, Tripathi N, Chigarira B, Sayegh N, Thomas VM, Li H, Jo Y, Gebrael G, Iyer Pu, Nussenzveig R, Agarwal N, Maughan BL, Gupta S, Swami U (2023). Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC). [Abstract]. 41, suppl 6; abstract 561.
    25. Li H, Sahu KK, Gebrael G, Chigarira B, Thomas VM, Jo Y, Kumar SA, Nordblad B, Brundage J, Tripathi N, Sayegh N, Swami U, Agarwal A, Maughan BL (2023). Clinical characteristics, tumor genomic and transcriptomic profiles of patients (pts) with metastatic renal cell carcinoma (mRCC) who developed venous thromboembolism (VTE). [Abstract]. 41, suppl 6; abstract 726.
    26. Sahu KK, Jo Y, Chigarira B, Kim JT, Sayegh N, Gebrael G, Tripathi N, Kumar SA, Thomas VM, Li H, Nussenzveig R, Kohli M, Gupta S, Maughan BL, Agarwal N, Swami U (2023). Correlation of age and the tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa). [Abstract]. 41, suppl 6; abstract 233.
    27. Sayegh N, Tripathi N, Chigarira B, Jo Y, Thomas VM, Nussenzveig R, Sahu KK, Li H, Gebrael G, Tandar C, Goel D, Rathi N, Maughan BL Swami U, Agarwal N (2023). Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer. [Abstract]. 41, suppl 6; abstract 235.
    28. Tripathi N, Li H, Chigarira B, Kumar SA, Kim JT, Sayegh N, Gebrael G, Jo Y, Sahu KK, Thomas VM, Nussenzveig R, Goel D, Tandar C, Rathi N, Swami U, Agarwal N, Maughan BL (2023). Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM). [Abstract]. 41, suppl 6; abstract 244.
    29. Lloyd J, Nordblad B, Sahu KK, Swami U, Phunrab TK, Batten JA, Maxwell L, Kohli M, Gupta S, Maughan BL, Agarwal N (2023). Investigating documented reasons for withdrawal from clinical trials for patients with advanced prostate cancer (PCa). [Abstract]. 41, suppl 6; abstract 105.
    30. Kohli M, Lee H, Lin T, Larsen M, Hanson C, Neibling A, Gupta S, Lloyd J, Maughan BL, Johnson SB, Agarwal N, Tward JD, Swami U, ONeil B, Dechet CB, Wang L, Tan A-C, Haaland B (2023). Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer. [Abstract]. 41, suppl 6; abstract 237.
    31. Seasor T, Balatico M, Chigarira B, Sahu KK, Kim JT, Matynia AP, Barry M, Albertson DJ, Mahlow J, Swami U, Agarwal N, Sirohi D (2023). Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies. [Abstract]. 41, suppl 6; abstract 259.
    32. Thomas VM, Sayegh N, Chigarira B, Gebrael G, Jo Y, Tripathi N, Nussenzveig R, Li H, Sahu KK, Tandar C, Goel D, Iyer P, Maughan BL, Swami U, Agarwal N (2023). Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to intensi铿乪d androgen deprivation therapy (i-ADT). [Abstract]. 41, suppl 6; abstract 234.
    33. Pelletier K, Balasubramanian I, Sahu KK, Cohan J, Kohli M, Maughan BL, Swami U, Agarwal N, Gupta S (2023). Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention. [Abstract]. 41, suppl 16; abstr e24027.
    34. Li H, Sahu KK, Gebrael G, Thomas VM, Tripathi N, Sayegh N, Maughan BL, Agarwal N, Swami U (2023). Access to National Cancer Institute (NCI) –designated cancer centers among Native American patients with cancer. [Abstract]. 41, suppl 16; abstr e18646.
    35. Gupta S, Maughan B, Kohli M, Cairns B, Swami U, Agarwal N (2022). A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE). [Abstract]. 10((Suppl 2; abstr 664)).
    36. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Mathew Thomas V, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. [Abstract]. 40(11), 493.e1-493.e7.
    37. Guven DC, Sayegh N, Tripathi N, Erman M, Agarwal N, Swami U (2022). Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis. [Abstract]. 40(16 suppl), 5079-5079.
    38. Sayegh N, Chigarira B, Hernandez EJ, McFarland TR, Li H, Sahu KK, Tripathi N, Kumar SA, Nordblad B, Goel D, Tandar C, Yandell M, Nussenzveig R, Sirohi D, Maughan BL, Swami U, Agarwal N (2022). Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior localized therapy (PLT-mCSPC).  [Abstract]. 40(16 suppl), 5080-5080.
    39. Greenberg S, Orlando E, Devlin M, Low S, Andon A, Neil Brock O, Kohlmann W, Wong B, Dechet CB, Sanchez A, Tward JD, Johnson SB, Agarwal N, Kohli M, Gupta S, Swami U, Maughan BL (2022). Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance? [Abstract]. 40(16 suppl), 5061-5061.
    40. Malangone-Monaco E, Li Weiyan, Noxon V, Jiang S, Amin S, Ghate S, Swami U, Agarwal N (2022). Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.  [Abstract]. 40(6).
    41. Greenberg S, Woelmer E, Devlin M, Low S, Anson A, Kohlmann W, Wong B, O Neil B, Dechet CB, Sanchez A, Tward JD, Johnson SB, Agarwal N, Kohli M, Gupta S, Swami U, Maughan BL (2022). Impact of pretest video genetic education in prostate cancer patients: Do patients need us? [Abstract]. 40(6).
    42. Sayegh N, Tripathi N, McFarland TR, Kessel A, Nussenzveig R, Chigarira B, Li H, Tandar C, Goel D, Nordblad B, Cheney J, Sahu KK, Maughan BL, Swami U, Agarwal N (2022). Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC).  [Abstract]. 40(6).
    43. Sayegh N, Tripathi N, Chigarira B, Jo Y, McFarland TR, Kessel A, Nussenzveig R, Li H, Tandar C, Goel D, Sahu KK, Haaland B, Maughan BL, Swami U, Agarwal N (2022). Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA ≤0.2 ng/Ml).  [Abstract]. 40(6).
    44. Swami U, Chigarira B, Sayegh N, McFarland TR, Tripathi N, Nussenzveig R, Kessel A, Tandar C, Goel D, Cheney J, Nordblad B, Thomas VM, Sirohi D, Maughan BL, Agarwal N (2022). Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).  [Abstract]. 40(6).
    45. Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Diessner B, Sandin R, Agarwal N (2022). Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.  [Abstract]. 40(6).
    46. Sayegh N, Jo Y, Tripathi N, McFarland TR, Kessel A, Nussenzveig R, Chigarira B, Li H, Tandar C, Sahu KK, Haaland B, Maughan BL, Swami U, Agarwal N (2022). Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.  [Abstract]. 40(6).
    47. Tripathi N, Li H, Jo Y, Sayegh N, Tandar C, Nussenzveig R, Haaland B, Cheney J, Goel D, Nordblad B, Gupta S, Maughan BL, Agarwal N, Swami U (2022). Tumor genomic landscape in younger compared to older patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). [Abstract]. 40(6).
    48. Gupta S, Grass GD, Maughan BL, Jain RK, Dechet CB, Sanchez A, ONeil B, Poch MA, Li R, Lloyd S, Tward JD, Phunrab TK, Hawks J, Swami U, Boucher KM, Agarwal N (2022). NEXT: A single-arm, phase 2, open-label study of adjuvant nivolumab after completion of chemo-radiation therapy in patients with localized muscle-invasive bladder cancer. [Abstract]. 40(6).
    49. Tripathi N, Jo Y, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC).  [Abstract]. 40(6).
    50. Chawla NS, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin ZB, Meza LA, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Phillip EJ, Bergerot CD, Lyou Y, Swami U, Gupta S, Maughan BL, Agarwal N, Pal SK (2022). Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.  [Abstract]. 40(6).
    51. Tagawa ST, Grivas P, Petrylak DP, Sternberg CN, Swami U, Bhatia A, Pichardo C, Goswami T, Loriot Y (2022). TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).  [Abstract]. 40(6).
    52. Tripathi N, Sayegh N, Jo Y, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Sirohi D, Swami U, Agarwal N, Maughan BL (2022). Tumor genomic landscape in smokers compared to non-smoker patients with locally advanced or metastatic urothelial carcinoma. [Abstract]. 40(6).
    53. Barata PC, Reisinger R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N (2021). Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA). (suppl 15; abstr 5058). [Abstract]. 39.
    54. Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, Sandin R, Agarwal N (2021). Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. (suppl 15; abstr 5072). [Abstract]. 39.
    55. Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li Haoran, Kohli M, Maughan BL, Goldkorn A, Agarwal N (2021). Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. (suppl 15; abstr 5077). [Abstract]. 39.
    56. Reisinger R, Santos VS, Nussenzveig R, Wesolowski S, Hernandez EJ, Henrie AR, Maughan BL, Swami U, Yandell M, Grivas P, Agarwal N (2021). Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP). J Clin Oncol 39, (suppl 15; abstr 4542). [Abstract]. 39.
    57. Florou V, Floudas CS, Maoz A, Naqash AR, Hildebrand G, Sokol E, Frampton GM, Puri S, Swami U, Wilky BA, Hosein PJ, Trent JC, Lopes G, Park W, Garrido-Laguna I (2021). Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB). (suppl 15; abstr 2599). [Abstract]. 39.
    58. Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL (2021). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. (suppl 6; abstr 135). [Abstract]. 39.
    59. McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N (2021). Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. J Clin Oncol 39, (suppl 6; abstr 166). [Abstract]. 39.
    60. Sayegh N, Swami U, Barata PC, Lilly MB, Nussenzveig R, Hensel C, Bryce AH, Bilen MA, Heath EI, Nandagopal L, Garje R, Saylor PJ, Babiker HM, Vaena DA, Kohli M, Pal SK, Sartor OA, Agarwal N (2021). Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA), J Clin Oncol, (suppl 6; abstr 256).     [Abstract]. 39.
    61. Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N (2021). Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). J Clin Oncol 39, (suppl 6; abstr 162). [Abstract]. 39.
    62. Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N (2021). Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. (suppl 6; abstr 59). [Abstract]. 39.
    63. Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA (2021). Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. (suppl 6; abstr 156). [Abstract]. 39.
    64. Freeman MM, Jaeger E, Zhu J, Phone A, Nussenzveig R, Caputo S, Ravindranathan D, Layton JL, Nandagopal L, Kessel A, Desai A, Koshkin VS, Basu A, Bilen MA, Swami U, Garcia JA, Agarwal A, Burgess EF, Sartor OA, Barata PC (2021). Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC)(suppl 6; abstr 17). [Abstract]. 39.
    65. Li H, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Sirohi D, Agarwal N, Maughan BL (2021). Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 39, (suppl 6; abstr 334). [Abstract]. 39.
    66. Zakharia Y, Reis R, Garje R, Swami U, Born JM, Brown JA, Nepple KG, Abuqayas B, Rajput M, Bellizzi A, Sieren JC, Rustum YM (2021). Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside. (suppl 6; abstr 322). [Abstract]. 39.
    67. Swami U, Sinnott JA, Haaland B, Maughan BL, Rathi N, McFarland TR, Kohli M, Nussenzveig R, Pal SK, Agarwal N (2020). Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset (suppl; abstr 5537). [Abstract]. 38.
    68. Swami U, Haaland B, Maughan BL, Nussenzveig R, Esther J, Kessel A, Pal SK, Grivas P, Agarwal N (2020). Comparative effectiveness of second-line (2L) single-agent atezolizumab (A), nivolumab (N), and pembrolizumab (P) in patients (Pts) with locally advanced or metastatic urothelial cancer (aUC) who progressed on platinum-based systemic chemotherapy (plat-chemo): Results from a real-world dataset (suppl; abstr 5032). [Abstract]. 38.
    69. Pokorny R, McPherson JP, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2020). Clinical outcomes with early-elective discontinuation of PD-1 inhibitors (PDi) at one year in patients (pts) with metastatic melanoma (MM) (suppl; abstr 10048). [Abstract]. 38.
    70. Lin E, Hahn AW, Nussenzveig R, Wesolowski S, Maughan BL, McFarland TR, Rathi N, Sartor AOO, Sonpavde G, Swami U, Kohli M, Rich TA, Yandell M, Agarwal N (2020). Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile (suppl; abstr e17596). [Abstract]. 38.
    71. Swami U, Isaacsson Velho PI, Nussenzveig R, Santos VS, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).  [Abstract]. 38.
    72. Hahn AW, Kessel A, McFarland TR, Swami U, Nussenzveig R, Esther J, Goel D, Sirohi D, Maughan BL, Agarwal N (2020). Response to systemic therapy and survival outcomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0 [Abstract]. 38.
    73. Esther J, Swami U, Chipman J, McFarland TR, Hahn AW, Sirohi D, Sharma P, Nussenzveig R, Agarwal N, Maughan BL (2020). Genomic alterations in visceral versus nonvisceral “metastatic” site tumor tissue in metastatic prostate cancer (mPC) [Abstract]. 38.
    74. Lin E, Wesolowski S, Nussenzveig R, McFarland TR, Swami U, Maughan BL, Yandell M, Agarwal N (2020). Identification of genomic alterations in signaling pathways associated with poor survival in newly diagnosed metastatic prostate cancer (mCSPC) using artificial intelligence (AI) [Abstract]. 38.
    75. Wesolowski S, Nussenzveig R, Santos VS, Esther J, Goel D, Swami U, Gupta S, Maughan BL, Yandell M, Grivas P, Agarwal N (2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI) [Abstract]. 38.
    76. Maughan BL, Nussenzveig R, Swami U, Gupta S, Agarwal N (2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response [Abstract]. 38.
    77. Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM (2020). Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma [Abstract]. 38.
    78. Maughan BL, Sanchez A, ONeil BB, Lowrance WT, Dechet CB, Albertson DJ, Sirohi D, Gupta S, Swami U, Agarwal N (2020). A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax) [Abstract]. 38.
    79. Rieth JM, Swami U, Greenlee J, Zanaty M, Bossler A, Jennings B, Henry M, Vanneste M, Mott S, Milhem MM (2019). Impact of surgery on outcomes in melanoma patients with brain metastases in the era of immunotherapy. The 16TH International Congress of the Society for Melanoma Research (SMR) [Abstract].
    80. Kaur A, Swami U, Fatima M, Ginn M, Stein J, Gao Y, Zakharia Y, Singh Y (2019). Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases, 2019 ACR/ARP Annual Meeting [Abstract].
    81. Sacristan Santos V, Esther J, Maughan B, Wesolowski S, Lin E, Hahn A, Sirohi D, Rathi N, Swami U, Nussenzveig R, Agarwal N (2019). Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS [Abstract]. 30(5).
    82. Swami U, Monga V, Knutson T, Bossler A, Zakharia Y, Milhem M (2018). Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma [Abstract]. J Clin Oncol, 36(suppl; abstr e21527).
    83. Swami U, Monga V, Tanas M, Bossler A, Mott S, Smith B, Milhem M (2017). A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi) in advanced soft tissue sarcomas (STS) [poster presentation also given at the American Association for Cancer Research Special Conference on Advances in Sarcomas: From Basic Science to Clinical Translation, Philadelphia, PA, May, 18, 2017 [Abstract]. Clinical Cancer Research, 24(2 suppl), B23.
    84. Goel S, Moran T, Coronado C, Ramirez SV, Chaudhary I, Ghalib MH, Swami U, Hou Y, Carcereny E, Alcantara J, Dios JLI, Miguel BD, Buges C, Rosell R (2017). Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors [Abstract].
    85. Pendurti G, Shah U, Swami U, Hou Y, Ghalib MH, Chaudhary I, Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S (2017). Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials [Abstract].
    86. Shah U, Pendurti G, Swami U, Hou Y, Ghalib MH, Chaudhary I, Mani S, Goel S, Aparo S (2017). Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience [Abstract].
    87. Swami U, Monga V, Zakhraia Y, Milhem M (2017). Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series [Abstract]. J Clin Oncol, 35(suppl 7S; abstract 123).
    88. Kam AE, Chaudhary I, Ghalib MH, Shah UH, Swami U, Kuo DYS, Hwang C, Elrafei TN, Cohen B, Gartrell BA, Kaledzi E, Chuy JW, Cheng H, Rajdev L, Haigentz M Jr, Mani S, Goel S (2017). Risks and benefits of phase I trials: Eighteen-year experience from a single institution [Abstract]. J Clin Oncol, 35(suppl; abstr e18146).
    89. Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J (2016). Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [Abstract].
    90. Chaudhary I, Rajdev L, Swami U, Wilhelm F, Cohen B, Haigentz M, Kaubisch A, Goel S, Mani S, Ghalib MH (2016). Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract].
    91. Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S (2016). Risks and Benefits of phase I trials: Twelve years experience from a single institution [Abstract].
    92. Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S (2016). Final results of a Phase I dose-escalation study of ON01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract].
    93. Swami U, Abbi KKS, Dozeman L, Tricot A, Tricot GJ (2016). Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM) [Abstract].
    94. Swami U, Abbi KKS, Dozeman L, Tricot A, Tricot GJ (2016). Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM) [Abstract]. Biology of Blood and Marrow Transplantation, 22(3), S177-8.
    95. Swami U, Dozeman L, Tricot A, Abbi KKS, Tricot GJ (2015). Collection of Peripheral Blood Stem Cells in Patients with Multiple Myeloma after Stem Cell Transplant: A Single Institution Experience [Abstract].
    96. Swami U, Dozeman L, Tricot A, Abbi KKS, Tricot GJ (2015). Collection of Peripheral Blood Stem Cells in Patients with Multiple Myeloma after Stem Cell Transplant: A Single Institution Experience [Abstract]. Blood, 126(23), 5435.
    97. Pendurti G, Shah U, Swami U, Hou Y, Ghalib MH, Chaudhary I, Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S (2015). Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials [Abstract]. J Clin Oncol, 33(suppl; abstr e14618).
    98. Shah U, Pendurti G, Swami U, Hou Y, Ghalib MH, Chaudhary I, Mani S, Goel S, Aparo S (2013). Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience [Abstract]. J Clin Oncol, 31(suppl; abstr e13550).
    99. Goel S, Moran T, Coronado C, Ramirez SV, Chaudhary I, Ghalib MH, Swami U, Hou Y, Carcereny E, Alcantara J, Dios JLI, Miguel BD, Buges C, Rosell R (2012). Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors [Abstract]. J Clin Oncol, 30(suppl; abstr 3093).
    100. Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S (2011). Risks and Benefits of phase I trials: Twelve years experience from a single institution [Abstract]. J Clin Oncol, 29(suppl; abstr 6098).
    101. Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S (2011). Final results of a Phase I dose-escalation study of ON01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 29(suppl; abstr e13584).
    102. Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J (2010). Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 28:15s(suppl; abstr 2589).
    103. Chaudhary I, Rajdev L, Swami U, Wilhelm F, Cohen B, Haigentz M, Kaubisch A, Goel S, Mani S, Ghalib MH (2010). Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 28(suppl; abstr e13133).
    104. Kurzrock R, Wheler J, Hong DS, Guo Z, Mulcahy MF, Benson III AB, Goel S, Swami U, Mani S, Buchbinder A (2009). Phase I, first in human dose escalation study of EZN-2208, a novel anticancer agent, in patients with advanced malignancies [Abstract].
    105. Kurzrock R, Wheler J, Hong DS, Guo Z, Mulcahy MF, Benson III AB, Goel S, Swami U, Mani S, Buchbinder A (2009). Phase I, first in human dose escalation study of EZN- 2208, a novel anticancer agent, in patients with advanced malignancies [Abstract]. Mol Cancer Ther, 8(12 suppl), C216.

    Newspaper

    1. Azeem Khan M, Florou V, Swami U (2021). Immunotherapy and fatigue: what we know and what we don't know. Oncotarget, pp. 719-720. ()

    Other

    1. Azeem Khan M, Florou V, Swami U (2021). Immunotherapy and fatigue: what we know and what we don't know. Oncotarget (12(8), pp. 719-720). United States. ()